Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Physician Treatment Preferences in Relapsed/Refractory Follicular Lymphoma: A Discrete Choice Experiment

John G. Gribben, Emmanuel Bachy, Markqayne Ray, Kathryn Krupsky, Kathleen Beusterien, Lewis Kopenhafer, Flor Mendez, Sara Beygi, Timothy Best, Graeme Ball, Kacper Perkowski, Patrick Olsen, Anik R Patel, Paola Ghione

Blood (2023) 142 (Supplement 1): 4424.

https://doi.org/10.1182/blood-2023-190261

Published: 2023

Journal Articles

Patient and Physician Preferences for Fixed-Duration Vs Treatment to Progression Chronic Lymphocytic Leukemia (CLL) Treatments: Results from a Multi-Country Discrete Choice Experiment

Bersabeh Sile, Dahbia Horchi, Bleuenn Rault, Emily Mulvihill, Kathleen Beusterien, Anna Teschemaker, Katherine Stewart, Paulo Andre P. Palhares De Miranda, Xavier Guillaume

Blood (2023) 142 (Supplement 1): 6528.

https://doi.org/10.1182/blood-2023-177690

Published: 2023

Journal Articles

Understanding Patient and Physician Perceptions Regarding Treatment-Related Adverse Events in First-Line Chronic Lymphocytic Leukemia (CLL)

Bersabeh Sile, Dahbia Horchi, Bleuenn Rault, Emily Mulvihill, Kathleen Beusterien, Katherine Stewart, Paulo Andre P. Palhares De Miranda, Xavier Guillaume

Blood (2023) 142 (Supplement 1): 6546.

https://doi.org/10.1182/blood-2023-177704

Published: 2023

Journal Articles

How Do Progression-Free Survival and Toxicity Risks Influence Oncologist and Patient Preferences for Novel Agents in Chronic Lymphocytic Leukemia?

Kellie Ryan, MPH, Hannah Le, PharmD, MPH, Svea K. Wahlstrom, VMD, MS, Kathleen Beusterien, MPH, Oliver Will, PhD, Martine C. Maculaitis, PhD, Thomas W. Leblanc

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-138952

Published: 2020